重症COVID-19患者血浆钙卫蛋白(S100A8/A9)升高与12个月死亡率和不良功能结局相关
这项前瞻性研究纳入2020年5月至2021年5月瑞典6个ICU的498例COVID-19患者,入住ICU时和第7天采血。主要终点为12个月死亡率。入院时和第7天高血浆钙卫蛋白与12个月死亡率独立相关;从入院至第7天钙卫蛋白升高与12个月死亡率(OR 2.10,95%CI 1.18-3.74,p=0.012)、3个月不良功能结局(OR 2.53,95%CI 1.07-6.10,p=0.036)、有创机械通气(OR 2.23,95%CI 1.10-4.53,p=0.027)和连续性肾脏替代治疗(OR 2.07,95%CI 1.07-4.00,p=0.031)独立相关。包含第7天钙卫蛋白和年龄的ROC模型对12个月死亡率预测良好(AUC 0.79,95%CI 0.74-0.84,p<0.001),第7天钙卫蛋白单独预测3个月不良功能结局(AUC 0.67,95%CI 0.58-0.76,p<0.001)。作者认为在ICU监测血浆钙卫蛋白动态可考虑用于评估重症COVID-19的预后。
要点
- 重症COVID-19患者从ICU入院至第7天血浆钙卫蛋白升高与12个月死亡率独立相关(OR 2.10,95%CI 1.18-3.74,p=0.012)。
- 钙卫蛋白升高与3个月不良功能结局(GOSE<5)独立相关(OR 2.53,95%CI 1.07-6.10,p=0.036)。
- 钙卫蛋白升高与ICU期间需要有创机械通气(OR 2.23,95%CI 1.10-4.53,p=0.027)和连续性肾脏替代治疗(OR 2.07,95%CI 1.07-4.00,p=0.031)独立相关。
- 包含第7天钙卫蛋白和年龄的ROC模型对12个月死亡率预测良好(AUC 0.79,95%CI 0.74-0.84,p<0.001)。
- 第7天钙卫蛋白单独预测3个月不良功能结局(AUC 0.67,95%CI 0.58-0.76,p<0.001);作者认为可考虑监测其动态评估预后。
适用人群与场景
- 2020年5月至2021年5月瑞典6个ICU收治的498例重症COVID-19患者。
- 纳入标准为入住ICU的COVID-19患者;原文未列出具体排除标准。
诊断标准与关键阈值
- 功能结局采用扩展格拉斯哥结局量表(GOSE,范围1-8),GOSE<5定义为不良功能结局。
- 血浆钙卫蛋白于ICU入院时和第7天采血检测。
研究设计与关键结果
- 前瞻性研究,纳入瑞典6个ICU的498例COVID-19患者,入住ICU时和第7天采血,主要终点为12个月死亡率。
- 入院时和第7天高血浆钙卫蛋白与12个月死亡率独立相关(校正年龄、性别、BMI、高血压、吸烟和肌酐)。
- 从入院至第7天钙卫蛋白升高与12个月死亡率独立相关:OR 2.10(95%CI 1.18-3.74),p=0.012。
- 钙卫蛋白升高与3个月不良功能结局独立相关:OR 2.53(95%CI 1.07-6.10),p=0.036。
- 钙卫蛋白升高与需要有创机械通气独立相关:OR 2.23(95%CI 1.10-4.53),p=0.027。
- 钙卫蛋白升高与需要连续性肾脏替代治疗独立相关:OR 2.07(95%CI 1.07-4.00),p=0.031。
- 包含第7天钙卫蛋白和年龄的ROC模型预测12个月死亡率:AUC 0.79(95%CI 0.74-0.84),p<0.001。
- 第7天钙卫蛋白单独预测3个月不良功能结局:AUC 0.67(95%CI 0.58-0.76),p<0.001。
证据类型、等级与局限
- 证据类型:前瞻性研究。
- 研究注册:ClinicalTrials.gov Identifier NCT04974775,注册于2020年4月28日。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在ICU监测血浆钙卫蛋白动态可考虑用于评估重症COVID-19的预后。
- 钙卫蛋白从入院至第7天升高与12个月死亡率、3个月不良功能结局、有创机械通气和连续性肾脏替代治疗独立相关,第7天钙卫蛋白联合年龄的模型对12个月死亡率预测良好(AUC 0.79)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Calprotectin (S100A8/A9) is a pro-inflammatory mediator primarily released from neutrophils. Previous studies have revealed associations between plasma calprotectin, disease severity and in-hospital mortality in unselected COVID-19 patients.
OBJECTIVE: We aimed to assess whether plasma calprotectin dynamics during the first week of intensive care are associated with mortality and functional outcome in critically ill COVID-19 patients.
METHODS: This prospective study included 498 COVID-19 patients admitted to six intensive care units (ICUs) in Sweden between May 2020 and May 2021. Blood samples were collected on ICU admission and on day 7. The primary outcome was 12-month mortality. Secondary outcomes were functional outcome of survivors at 3 and 12 months, and the need for invasive mechanical ventilation (IMV) or continuous renal replacement therapy (CRRT) during the ICU stay. Functional outcome was assessed by the Glasgow Outcome Scale Extended (GOSE, range 1-8, with < 5 representing an unfavourable outcome). Associations between plasma calprotectin and outcomes were examined in binary logistic regression analyses adjusted for age, sex, BMI, hypertension, smoking, and creatinine.
RESULTS: High plasma calprotectin on admission and day 7 was independently associated with increased 12-month mortality. Increasing calprotectin from admission to day 7 was independently associated with higher mortality at 12 months [OR 2.10 (95% CI 1.18-3.74), p = 0.012], unfavourable functional outcome at 3 months [OR 2.53 (95% CI 1.07-6.10), p = 0.036], and the use of IMV [OR 2.23 (95% CI 1.10-4.53), p = 0.027)] and CRRT [OR 2.07 (95% CI 1.07-4.00), p = 0.031)]. A receiver operator characteristic (ROC) model including day 7 calprotectin and age was a good predictor of 12-month mortality [AUC 0.79 (95% CI 0.74-0.84), p < 0.001]. Day 7 calprotectin alone predicted an unfavourable functional outcome at 3 months [AUC 0.67 (95% CI 0.58-0.76), p < 0.001].
CONCLUSION: In critically ill COVID-19 patients, increasing calprotectin levels after admission to the ICU are associated with 12-month mortality and unfavourable functional outcome in survivors. Monitoring plasma calprotectin dynamics in the ICU may be considered to evaluate prognosis in critical COVID-19.
STUDY REGISTRATION: ClinicalTrials.gov Identifier: NCT04974775, registered April 28, 2020.
参考来源
- Didriksson I, Lengquist M, Spångfors M, et al. Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients. J Intensive Care. 2024. PMID: 38982551. doi:10.1186/s40560-024-00740-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。